中文
English
한국어
日本語
Español
Français
Русский
| カタログ番号 | HB613014 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 説明 |
Anti-CD223/LAG3 Polyclonal Antibody (HB613014) is a rabbit polyclonal antibody detecting CD223 in ELISA, IHC, WB. Suitable for Human.
Highlights
|
||||||||
| 種反応性 | Human | ||||||||
| アプリケーション | ELISA, IHC, WB | ||||||||
| 宿主種 | Rabbit | ||||||||
| クローン性 | Polyclonal | ||||||||
| アイソタイプ | IgG | ||||||||
| 免疫原 | E. coli - derived recombinant Human CD223/LAG3 (Leu23-Leu450). | ||||||||
| ターゲット | CD223, FDC, LAG-3, LAG3, Lymphocyte activation gene 3 protein, Secreted lymphocyte activation gene 3 protein, sLAG-3 | ||||||||
| エンドトキシンレベル | Please contact with the lab for this information. | ||||||||
| 純度 | >90% as determined by SDS-PAGE. | ||||||||
| 精製 | Purified by antigen affinity column. | ||||||||
| アクセッション番号 | P18627 | ||||||||
| 形態 | Liquid | ||||||||
| 保存バッファー | 0.01M PBS, pH 7.4, 50% glycerol, 0.05% Proclin 300. データシートのハードコピーまたはロット固有のCOAに記載された具体的なバッファー情報を参照してください。 |
||||||||
| 製品使用情報 |
| ||||||||
| 安定性と保存 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. | ||||||||
| 背景 | Lymphocyte activation gene 3 protein (CD223/LAG3) is a ~57 kDa protein. Inhibitory receptor on antigen activated T-cells. Delivers inhibitory signals upon binding to ligands, such as MHC class II, its main ligand present at the surface of antigen-presenting cells (APCs), and FGL1, which is secreted by hepatocytes and certain types of tumor cells. Ligand-binding initiates a signaling that inhibits the T-cell receptor (TCR) in the immunological synapse, preventing T-cell activation. Mechanistically, ligand-binding promotes (1) ubiquitination of the KIEELE motif, unleashing the RRFSALE motif from the membrane and (2) leading to the formation of condensates with the TCR component CD3E, thereby disrupting the association between CD3E and LCK and preventing TCR activation. May inhibit antigen-specific T-cell activation in synergy with PDCD1/PD-1. CD223 is the therapeutic target of relatlimab (Opdualag). 1. Camisaschi, C. et al. (2010) Journal of immunology (Baltimore, Md. : 1950) 184, 6545-51. PMID: 20421648 2. Ming, Q. et al. (2022) Nature immunology 23, 1031-1041. PMID: 35761082 3. Huard, B. et al. (1994) European journal of immunology 24, 3216-21. PMID: 7805750 4. Huard, B. et al. (1996) European journal of immunology 26, 1180-6. PMID: 8647185 5. Wang, J. et al. (2019) Cell 176, 334-347.e12. PMID: 30580966 6. MacLachlan, BJ. et al. (2021) European journal of immunology 51, 331-341. PMID: 32920841 7. Petersen, J. et al. (2024) Science immunology 9, eads5122. PMID: 39671469 8. Huard, B. et al. (1995) European journal of immunology 25, 2718-21. PMID: 7589152 10. Jiang, Y. et al. (2025) Cell 188, 2354-2371.e18. PMID: 40101708 | ||||||||
| 注意事項 | For research use only. |
+86-027-65523339
中国武漢市深敦寺路666号C棟、武漢、430206
